Today's noteworthy upgrades include: ABM Industries (ABM) upgraded to Outperform at RW Baird... Alibaba (BABA) upgraded to Buy from Hold at Stifel... Autohome (ATHM) upgraded to Overweight from Equal Weight at Barclays... BJ's Restaurants (BJRI) upgraded to Outperform from Neutral at Wedbush... Black Diamond (BDE) upgraded at Stifel... Cabot Oil & Gas (COG) upgraded to Buy from Accumulate at Global Hunter... Charles Schwab (SCHW) upgraded at JMP Securities... Diamondback Energy (FANG) upgraded to Buy from Accumulate at Global Hunter... Energen (EGN) upgraded to Neutral from Reduce at Global Hunter... Gastar Exploration (GST) upgraded to Buy from Accumulate at Global Hunter... Investors Bancorp (ISBC) upgraded to Overweight from Equal Weight at Barclays... JD.com (JD) upgraded to Outperform from Market Perform at William Blair... Lancaster Colony (LANC) upgraded to Neutral from Underperform at Hilliard Lyons... Lexington Realty (LXP) upgraded to Buy from Neutral at Ladenburg... Moody's (MCO) upgraded at Evercore ISI... Parsley Energy (PE) upgraded to Accumulate from Neutral at Global Hunter... Ring Energy (REI) upgraded to Buy from Accumulate at Global Hunter... SM Energy (SM) upgraded to Buy from Accumulate at Global Hunter... Sanofi (SNY) upgraded to Outperform from Market Perform at Leerink... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... State Street (STT) upgraded at Bernstein... Walker & Dunlop (WD) upgraded to Outperform from Market Perform at Keefe Bruyette.

Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."